The diagnostic potential of the iron regulatory hormone hepcidin
Hal Drakesmith
MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, John
Radcliffe Hospital, Oxford, United Kingdom / Haematology Theme, Oxford Biomedical Research Centre, Oxford, United Kingdom
EHA Library. Armitage A. Jun 15, 2019; 273688
Andrew Armitage
Andrew Armitage
Learning Objectives

Martina U. Muckenthaler - Chair introduction

Systemic iron homeostasis is maintained by the iron-regulated peptide hormone hepcidin and its target receptor, the iron exporter ferroportin. The hepcidin/ferroportin regulatory axis prevents diseases of iron overload (ie, Hereditary hemochromatosis, thalassemia) or iron deficiency (ie, anemia). In this session, we will discuss pathologies underlying these frequent disorders and dissect mechanisms that cause functional or absolute iron overload or deficiency. We will explore novel approaches to oral iron treatment, the value of hepcidin as a diagnostic marker and how novel therapeutics just entering clinical trials modulate plasma iron availability via the hepcidin/ferroportin regulatory system. This session provides an exciting example for how knowledge derived from basic research can be translated into the clinic.

Learning goals of the article
The aim of this educational session is to generate novel insight into.
• frequent pathologies caused by a misregulation of the hepcidin/ferroportin system.
• novel approaches to oral iron treatment.
• diagnosis of iron-related disorders.

Learning goals of the presentation
After attending this lecture, the participant will be able to
• understand how the iron-regulatory hormone hepcidin: controls systemic iron homeostasis, is regulated by a balance of signals related to iron status, inflammatory status, erythropoiesis and hypoxia, is involved in the pathogenesis of a range of iron-related disorders,
• describe clinical and global health contexts in which hepcidin shows promise as a diagnostic indicator,
• recognise analytical factors that must be considered for appropriate interpretation of hepcidin data, and
• appreciate steps that will be required to facilitate routine implementation of hepcidin measurement in clinical practice and epidemiological surveys.

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies